期刊
JOURNAL OF HEPATOLOGY
卷 46, 期 3, 页码 403-410出版社
ELSEVIER
DOI: 10.1016/j.jhep.2006.09.019
关键词
HCV; core region; LDL cholesterol; peginterferon; ribavirin; early virologic response; sustained virological response; mutation-specific primer; double-wild type; ICG R15
Background/Aims: We showed previously that amino acid (aa) substitutions in the HCV core region (HCV-CR) are predictors of non-virological response (NVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy. Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment. Methods: We evaluated the response to 48-week PEG-IFN-RBV therapy in 114 Japanese adults infected with HCV genotype 1b and determined the predictors of EVR and SVR. Results: EVR was achieved by 70% and SVR by 45% of patients. 64% of patients who achieved EVR also showed SVR, while none of non-EVR achieved SVR. Multivariate analysis identified low-density lipoprotein cholesterol (LDL-C) (>= 86 mg/dl), aa substitutions in HCV-CR (double-wild-type; arginine at aa 70/leucine at aa 91), gamma-glutamyl trans-peptidase (GGT) (< 109 IU/1), RBV dose (>= 11.0 mg/kg), and leukocyte count (>= 4500/mm(3)) as significant determinants of EVR, and aa substitutions in HCV-CR (double-wild-type), LDL-C (>= 86 mg/dl), male gender, ICG R15 (< 10%), GGT (< 109 IU/1), and RBV dose (>= 11.0 mg/kg) as determinants of SVR. Prediction of response to therapy based on combination of these factors had high sensitivity, specificity, positive, and negative predictive values. Conclusions:Our study identified aa substitutions in the core region and serum LDL-C as predictors of response to PEG-IFN-RBV therapy in Japanese patients infected with HCV genotype 1b. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据